Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial
Open Access
- 13 February 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (2) , e0229068
Abstract
Kyoto University Substance (KUS) 121, an ATPase inhibitor of valosin-containing protein, is a novel neuroprotectant. We tested the safety and effectiveness of KUS121 in patients with acute central retinal artery occlusion (CRAO). We conducted an investigator-initiated, first-in-humans, phase 1/2 clinical trial. Nine patients with non-arteritic CRAO symptoms lasting for 4–48 h were enrolled. These patients received daily intravitreal injections of KUS121 for 3 days: 25 μg (low-dose) in the first three patients and 50 μg (high-dose) in the next six patients. The primary endpoint was the safety of the drug. As a secondary endpoint, pharmacokinetics was evaluated. Other key secondary endpoints were changes in best-corrected visual acuity (BCVA), measured using the Early Treatment Diabetic Retinopathy Study chart, visual field scores, and retinal sensitivities between baseline and week 12; and decimal BCVA at week 12. Administration of KUS121 did not result in serious adverse events. All nine patients (100%) showed significant improvement of BCVA. Average readable letter counts, visual field scores, and retinal sensitivities also improved. Decimal BCVA at week 12 was better than 0.1 in four patients (44%) and equal to or better than 0.05 in seven patients (78%). This first-in-humans clinical trial provides support for the safety and efficacy of intravitreal KUS121 injection. To substantiate the safety and effectiveness for patients with acute CRAO, further larger scale clinical studies will be needed.Keywords
Funding Information
- Japan Agency for Medical Research and Development (H28C13, 17lm0203012h0001, and 18lm0203012h0002)
- Ministry of Health, Labour and Welfare
- Kyoto Drug Discovery & Development Co., Ltd.
This publication has 28 references indexed in Scilit:
- Evidence for an enduring ischaemic penumbra following central retinal artery occlusion, with implications for fibrinolytic therapyProgress in Retinal and Eye Research, 2015
- Nationwide Incidence of Clinically Diagnosed Central Retinal Artery Occlusion in Korea, 2008 to 2011Ophthalmology, 2014
- The Incidence of Central Retinal Artery Occlusion in Olmsted County, MinnesotaAmerican Journal of Ophthalmology, 2011
- Efficacy of Intravenous Tissue-Type Plasminogen Activator in Central Retinal Artery OcclusionStroke, 2011
- Study of the Efficacy of Intravenous Tissue Plasminogen Activator in Central Retinal Artery OcclusionInternational Journal of Stroke, 2011
- Central Retinal Artery Occlusion: Local Intra-arterial Fibrinolysis versus Conservative Treatment, a Multicenter Randomized TrialOphthalmology, 2010
- Surgical embolus removal in retinal artery occlusionBritish Journal of Ophthalmology, 2006
- Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no. 1Graefe's Archive for Clinical and Experimental Ophthalmology, 2005
- Central retinal artery occlusion.Experimental Eye Research, 2004
- The Incidence of Central Retinal Artery Occlusion in the District of Split, CroatiaOphthalmologica, 2001